Ask-the-Expert Online Conference
- Question from Nunz: Why is tamoxifen recommended for women with LCIS if we aren't sure it's estrogen-receptor-positive?
- Answers - Lynn Hartmann In the large U.S. prevention trial on non-invasive disease women with lobular carcinoma in situ (LCIS) were eligible. There was a significant reduction of their risk of subsequent breast cancer with tamoxifen. So we consider tamoxifen a valid option for women with LCIS.
- Beth Baughman DuPree, M.D., F.A.C.S. LCIS is not cancer; it is a marker for an elevated risk of developing breast cancer. Therefore, the rationale for using tamoxifen is for those cancers that are estrogen-receptor-positive, we are attempting to block those cells from dividing and turning into cancer. Tamoxifen would not be effective in tumors that are estrogen-receptor-negative, but a majority of breast cancers are estrogen-receptor-positive. Therefore, we derive the benefit of tamoxifen from that fact.
This Ask-the-Expert Online Conference called Risk Reduction featured Beth Baughman DuPree, M.D., F.A.C.S. and Lynn Hartmann answering your questions about breast cancer risk factors and ways to lower your risk.
Editor's Note: This conference took place in February 2006.
The materials presented in these conferences do not necessarily reflect the views of Breastcancer.org. A qualified healthcare professional should be consulted before using any therapeutic product or regimen discussed. All readers should verify all information and data before employing any therapies described here.
A production of LiveWorld, Inc.
Copyright 2010. All rights reserved.